China Approves Satri-cel: First-Ever CAR-T Therapy for Solid Tumors Marks Historic Milestone in Gastric Cancer
核心洞察
China has approved satri-cel (CLDN18.2 (搜索) CAR-T) for advanced gastric/GEJ cancer, making it the first CAR-T therapy ever approved for a solid tumor.
The pivotal CT041-ST-01 trial showed median overall survival of 7.9 months with satri-cel versus 5.5 months with physician's choice (HR 0.69), with an 18-month OS rate of 20% versus 10%.
Median progression-free survival was 3.25 months versus 1.77 months (HR 0.37), demonstrating superiority in a heavily pretreated, third-line or later population.
China has approved satri-cel, a CLDN18.2 (搜索)-targeted chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancer, marking the first time a CAR-T therapy has received regulatory authorization for any solid tumor indication. The approval, described as "a historic day for solid tumor oncology," shatters a long-standing barrier that had confined CAR-T therapies to hematologic malignancies while solid tumors remained beyond reach.
The decision is grounded in results from the CT041-ST-01 trial, a study evaluating satri-cel in a heavily pretreated, third-line or later (3L+) patient population with CLDN18.2 (搜索)-positive advanced gastric or GEJ cancer. The data, published in The Lancet, demonstrated a statistically significant improvement over physician's choice therapy across multiple endpoints.
Efficacy Outcomes in a Heavily Pretreated Population
In the pivotal trial, satri-cel achieved a median progression-free survival (PFS) of 3.25 months compared with 1.77 months in the control arm, yielding a hazard ratio (HR) of 0.37. Median overall survival (OS) reached 7.9 months with satri-cel versus 5.5 months with physician's choice therapy (HR 0.69). The 18-month OS rate was 20% in the satri-cel arm compared with 10% in the control group, indicating a doubling of long-term survival in this difficult-to-treat population.
While the absolute survival gains — a 2.4-month improvement in median OS — may appear modest, experts emphasize that the significance of this approval extends far beyond the numerical results. As Nicholas Hornstein, MD, PhD, Assistant Professor at Northwell Health and GI Medical Oncologist, noted: "The absolute numbers are not dramatic, but that isn't the point. This is the first regulatory approval of a CAR-T for a solid tumor."
A Shift in the Global Oncology Innovation Landscape
The approval also highlights a notable geographic shift in oncology drug development. "Also notable: this happened in China, not the United States," Hornstein observed. "As China continues to accelerate development of cell therapies, ADCs, and other oncology platforms, it is increasingly becoming the site of first-in-class innovation."
Satri-cel targets claudin 18.2 (CLDN18.2 (搜索)), a tight junction protein that is frequently overexpressed in gastric and GEJ cancers and represents an attractive target for cellular immunotherapy. The approval validates CLDN18.2 as a clinically actionable target in solid tumors and opens the door for further CAR-T development in epithelial malignancies.
The Beginning of the Solid Tumor CAR-T Era
The regulatory milestone carries profound implications for the field. "Satri-cel may ultimately be remembered less for the 2.4-month OS gain and more for what it represents: the beginning of the solid tumor CAR-T era," Hornstein stated. For years, CAR-T therapies have transformed outcomes in hematologic malignancies, yet solid tumors — which constitute the vast majority of cancer diagnoses — remained an elusive frontier due to challenges including the immunosuppressive tumor microenvironment, antigen heterogeneity, and limited T-cell infiltration.
This approval provides proof-of-concept that CAR-T therapy can be successfully deployed against solid tumors, potentially catalyzing investment and research across a broad range of epithelial cancer types. The demonstration of superiority over physician's choice therapy in a heavily pretreated population further underscores the therapeutic potential of this approach in settings of high unmet need.